Ultragenyx

Last updated
Ultragenyx Pharmaceutical Inc.
Company type Public company
Industry
Founded2010;14 years ago (2010)
Headquarters
Novato, California
,
U.S.
Areas served
International
Key people
 Emil Kakkis
(president & founder)
Products
RevenueIncrease2.svg US$271 million (2020) [1]
Number of employees
893 (2020)
Website ultragenyx.com

Ultragenyx is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Contents

Ultragenyx is based in Novato, CA and Brisbane, CA [2] and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. [3] The company’s Latin American headquarters is located in Miami. [4]

Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. [5] Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. [6] The company also has therapies approved outside the U.S. in Canada, Latin America, Europe, and Japan. [7]

In 2020 and 2021, Ultragenyx was named one of Deloitte's fasting growing technology and life sciences companies in North America [8] and one of the best companies to work for by BioSpace. [9] Also in 2021, the company’s CEO, Emil Kakkis, was awarded the California Life Sciences Pantheon Leadership award. [10]

History

Ultragenyx Pharmaceutical Inc. was founded in 2010 by Emil Kakkis based on his history of developing therapies for rare disease starting at Harbor-UCLA Medical Center, continuing through his role as chief medical officer of BioMarin and as founder of the EveryLife Foundation. [11] He became the chief executive officer and president, focusing the company to meet the treatment needs for rare diseases understood as affecting fewer than 200,000 people in the U.S. [12] [13] In 2014 the USA-based company went public with an IPO that raised $126 million. [14] In 2015 Ultragenyx began collaborating with Arcturus Therapeutics to develop mRNA products. [15]

Ultragenyx acquired Dimension Therapeutics in 2017 [16] to obtain adeno-associated virus (AAV)-based gene therapy manufacturing technology as well as three internal candidates and one partnered candidate with Bayer for hemophilia A. [17]

In 2017, the company discontinued development of Ace-ERs treatment for GNE myopathy after the product didn't meet the study's primary endpoint which was significant improvement in arm strength. It also failed to meet three key secondary endpoints that evaluated patients' physical functions, leg muscle strength and knee extension force. [18] Previous trials in mice had shown efficacy. [19]

In 2020 Ultragenyx announced a new gene therapy plant being built near Boston. [20]

In July 2022 Ultragenyx announced that it would exercise its option to acquire GeneTx Biotherapeutics for an up-front cash payment of $75 million, plus another $115 million in potential milestone-dependent payments. Ultragenyx will add the antisense oligonucleotide therapy GTX-102 to its broad pipeline of therapies indicated for various rare diseases. GTX-102 is currently in early-stage development for Angelman syndrome. [21] The deal was completed in August 2022.

Products

Pipeline

Biologic

Gene therapy

ASO/mRNA

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.

Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. Several ASOs have been approved in the United States, the European Union, and elsewhere.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

<span class="mw-page-title-main">PTC Therapeutics</span> Pharmaceutical company

PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

<span class="mw-page-title-main">United Therapeutics</span> American biotech company based in Maryland

United Therapeutics Corporation is an American publicly traded biotechnology company and public benefit corporation listed on the NASDAQ under the symbol UTHR. It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.

<span class="mw-page-title-main">Spark Therapeutics</span> American pharmaceutical company

Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases. It is a subsidiary of Hoffmann-La Roche.

<span class="mw-page-title-main">Intellia Therapeutics</span> American biotechnology company

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

References

  1. ↑ "Ultragenyx Pharmaceutical Revenue 2012-2021 | RARE".
  2. ↑ "Ultragenyx reports nearly $73M Q3 loss as R&D spending up 30%". The North Bay Business Journal. 2021-11-03. Retrieved 2022-02-23.
  3. ↑ "Rare disease drug maker Ultragenyx plans to hire 100-150 at new gene therapy facility near Boston". www.bizjournals.com. Retrieved 2022-02-23.
  4. ↑ Bartucci, Camila (2021-11-23). "Ultragenyx abre central en Miami, Latam". PharmaBiz.NET (in Spanish). Retrieved 2022-03-03.
  5. ↑ Denworth, Lydia (2020). "Is gene therapy ready to treat some forms of autism?". Science. doi:10.1126/science.abf2497. S2CID   242454742.
  6. ↑ "Novato Firm Partners With Rival To Treat Rare Illness". Novato, CA Patch. 2022-01-21. Retrieved 2022-03-15.
  7. ↑ "Health Canada Approves Ultragenyx' Drug for Group of Rare Metabolic Disorders". Global Genes. 2021-02-17. Retrieved 2022-03-18.
  8. ↑ "2021 Technology Fast 500 Award Winners". Deloitte United States. Retrieved 2022-03-18.
  9. ↑ "BioSpace | Best Places to Work jobs | Choose from 3,724 live job openings". www.biospace.com. Retrieved 2022-03-22.
  10. ↑ "Marin County pharmaceuticals CEO wins lifetime achievement award". The North Bay Business Journal. 2021-11-17. Retrieved 2022-03-25.
  11. ↑ "Providence Dr Emil Kakkis". NorthBay biz. Retrieved 2022-02-25.
  12. ↑ "The road to a 'miracle drug': How Ultragenyx and partners found their way to the newest rare disease treatment". www.bizjournals.com. Retrieved 2022-03-08.
  13. ↑ Commissioner, Office of the (2020-10-05). "Rare Diseases at FDA". FDA. Retrieved 2022-03-08.
  14. ↑ "Ultragenyx raises $126 million in IPO". February 5, 2014.
  15. ↑ Writer, GEN Staff (2015-10-29). "Ultragenyx, Arcturus Launch Up-to-$1.56B+ Rare Disease Collaboration". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-02-15.
  16. ↑ "Bruised Ultragenyx attempts swoop for in-demand Dimension". September 18, 2017.
  17. ↑ Writer, GEN Staff (2017-10-02). "Dimension Therapeutics Spurns Regenxbio for Sweeter Ultragenyx Offer". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-02-09.
  18. 1 2 "Ultragenyx shelves genetic disease drug after trial failure". August 23, 2017.
  19. ↑ Takeda. Translational Research in Muscular Dystrophy , p. 72, at Google Books
  20. ↑ "Rare disease drug maker Ultragenyx plans to hire 100-150 at new gene therapy facility near Boston". www.bizjournals.com. Retrieved 2022-03-17.
  21. ↑ "Ultragenyx Pharmaceutical". July 19, 2022.
  22. ↑ Writer, GEN Staff (2017-11-16). "FDA Approves Ultragenyx Enzyme Replacement Therapy for MPS VII". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-02-10.
  23. ↑ Lamb, Y. N. (2018). "Burosumab: First Global Approval". Drugs. 78 (6): 707–714. doi:10.1007/s40265-018-0905-7. PMID   29679282. S2CID   5022649.
  24. ↑ "Specialty Pipeline Monthly Update" (PDF). September 2018.
  25. ↑ "Crysvita Approved for Treatment of Tumor-Induced Osteomalacia". MPR. 2020-06-22. Retrieved 2022-02-04.
  26. ↑ "FDA Greenlights Ultragenyx's Dojolvi for Long-Chain Fatty Acid Oxidation Disorders". BioSpace. Retrieved 2022-02-10.
  27. ↑ Bulik, Beth Snyder (2021-01-29). "Ultragenyx earns 2 rare disease drug approvals—and a validated commercial strategy". Fierce Pharma. Retrieved 2022-03-25.
  28. ↑ Sagonowsky, Eric (2021-02-11). "Regeneron's Evkeeza, carrying big price tag, wins FDA approval in ultra-rare cholesterol disease". Fierce Pharma. Retrieved 2022-03-11.
  29. ↑ Adams, Ben (2022-01-07). "Regeneron hands over Evkeeza rights to Ultragenyx outside US, with an R&D asset also thrown in". Fierce Pharma. Retrieved 2022-03-11.
  30. ↑ "Mereo BioPharma Group Pact With Ultragenyx Pharmaceutical to Develop Setrusumab to Strengthen Bones". December 21, 2020.
  31. 1 2 "Company Growth, Ambition Drive Ultragenyx's Continued Success". BioSpace. Retrieved 2022-03-03.
  32. ↑ PhD, Marta Figueiredo. "First 2 Adults with Severe Hemophilia A Respond Well to Gene… – Hemophilia News Today" . Retrieved 2022-03-17.
  33. ↑ "Astra gets Wilson disease bonus". Evaluate.com. 2021-08-26. Retrieved 2022-03-22.
  34. ↑ PhD, Aisha I. Abdullah. "Ultragenyx and Solid Biosciences Partner on DMD Gene Therapy – Muscular Dystrophy News" . Retrieved 2022-03-25.
  35. ↑ "A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome (KIK-AS)". 2020.
  36. ↑ "GeneTx and Ultragenyx Announce Investigational New Drug (IND)". CNN . January 15, 2020.
  37. ↑ Carpenter, T. O.; Whyte, M. P.; Imel, E. A.; Boot, A. M.; Högler, W.; Linglart, A.; Padidela, R.; Van't Hoff, W.; Mao, M.; Chen, C. Y.; Skrinar, A.; Kakkis, E.; San Martin, J.; Portale, A. A. (2018). "Burosumab Therapy in Children with X-Linked Hypophosphatemia". The New England Journal of Medicine. 378 (21): 1987–1998. doi:10.1056/NEJMoa1714641. hdl: 1805/18603 . PMID   29791829. S2CID   44135503.
  38. ↑ "Biotech Companies Announce Big Drug Wins with FDA". BioSpace. Retrieved 2022-02-25.
  39. ↑ "mRNA therapeutics - Arcturus Therapeutics/Ultragenyx Pharmaceutical". Adis Insights, Springer. 21 Jun 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.